In PCa, EZH2‐regulated deubiquitination of FOXA1 via USP7 promotes FOXA1 protein stability, suggesting that patients with high FOXA1 expression may have greater sensitivity to targeted therapies [64]. The gene discussed is USP7; the disease is posterior cortical atrophy.